Mark Sheptoff Financial Planning LLC Invests $57,000 in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Mark Sheptoff Financial Planning LLC acquired a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,500 shares of the company’s stock, valued at approximately $57,000.

A number of other institutional investors have also recently added to or reduced their stakes in TEVA. Victory Capital Management Inc. lifted its position in shares of Teva Pharmaceutical Industries by 21.9% during the 4th quarter. Victory Capital Management Inc. now owns 38,386 shares of the company’s stock valued at $401,000 after acquiring an additional 6,886 shares during the period. Private Advisor Group LLC increased its position in shares of Teva Pharmaceutical Industries by 31.5% in the fourth quarter. Private Advisor Group LLC now owns 19,424 shares of the company’s stock valued at $204,000 after buying an additional 4,654 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its position in shares of Teva Pharmaceutical Industries by 14.5% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 16,138 shares of the company’s stock valued at $168,000 after buying an additional 2,041 shares in the last quarter. Norges Bank acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth $14,376,000. Finally, Hsbc Holdings PLC boosted its position in shares of Teva Pharmaceutical Industries by 242.6% in the 4th quarter. Hsbc Holdings PLC now owns 1,597,178 shares of the company’s stock worth $16,667,000 after buying an additional 1,130,969 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on TEVA. UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Bank of America upped their target price on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, May 30th. Jefferies Financial Group raised their price target on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 3rd. Finally, Barclays lifted their price objective on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.89.

Teva Pharmaceutical Industries Stock Up 0.2 %

Teva Pharmaceutical Industries stock opened at $17.88 on Thursday. The stock has a fifty day moving average price of $17.65 and a 200 day moving average price of $16.03. Teva Pharmaceutical Industries Limited has a 52 week low of $8.06 and a 52 week high of $19.08. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, beating the consensus estimate of $0.55 by $0.03. The company had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. As a group, analysts expect that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the transaction, the insider now owns 45,060 shares in the company, valued at approximately $777,285. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.55% of the stock is currently owned by company insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.